The invention relates to a pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles, wherein the DPP-IV inhibitor is in free form or in form of a salt thereof, wherein at least 45 wt.% of the DPP-IV inhibitor particles and DPP-IV inhibitor agglomerates have a size when measured using sieve analysis of more than 250 µm. The pharmaceutical formulation shows improved stability and allows easy production of solid oral dosage forms due to the good flow properties of the particles and agglomerates.